Discusses all aspects of novel and emerging therapies for myeloma and other plasma cell neoplasms

Includes new diagnostic criteria for multiple myeloma

Presents recently acquired data relating to prognosis and minimal residual disease

Autorentext

Klappentext
This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström's macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.

Inhalt
Epidemiology and Molecular Pathophysiology of Multiple Myeloma.- Diagnosis and Staging.- Treatment of Transplant Eligible Patients with Multiple Myeloma.- Treatment of Elderly Patients with Multiple Myeloma.- Treatment of Relapsed/Refractory Patients with Multiple Myeloma.- Immunotherapy for Multiple Myeloma.- Minimal Residual Disease in Multiple Myeloma.- Bone Disease.- Other Complications of Multiple Myeloma.- Plasma Cell Leukemia and Extramedulary Plasmacytoma.- POEMS.- Waldenstrom s Macroglobulinemia.- Primary Systemic Amyloidosis.